Cytosorbents (CTSO) EBT (2010 - 2026)

Cytosorbents (CTSO) has reported EBT for 17 consecutive years, with -$3.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 17.14% year-over-year to -$3.5 million; the trailing twelve-month figure through Jun 2026 stood at -$17.5 million (up 1.42% YoY), and the FY2025 full-year result was -$9.6 million, up 57.13% from the prior year.
• EBT climbed to -$3.5 million in Q2 2026 per CTSO's latest filing, from -$3.9 million in the prior quarter.
• Across five years, EBT topped out at -$1.5 million in Q1 2025 and bottomed at -$12.2 million in Q3 2022.
• Historically, EBT has averaged -$6.1 million across 5 years, with a median of -$6.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: EBT soared 81.49% in 2022, then plunged 297.48% in 2023.
• Over 5 years, EBT stood at -$1.9 million in 2022, then slumped by 297.48% to -$7.4 million in 2023, then dropped by 25.31% to -$9.3 million in 2024, then rose by 29.73% to -$6.5 million in 2025, then soared by 46.11% to -$3.5 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$3.5 million, -$3.9 million, and -$6.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.